Aliskiren—mode of action and preclinical data

@article{Mller2008AliskirenmodeOA,
  title={Aliskiren—mode of action and preclinical data},
  author={Dominik N. M{\"u}ller and Wolfgang Derer and Ralf Dechend},
  journal={Journal of Molecular Medicine},
  year={2008},
  volume={86},
  pages={659-662}
}
Hypertension is one of the major health care problems worldwide since it markedly increases the risk for development of heart disease, stroke, generalized vascular disease, and renal failure. The renin–angiotensin system (RAS) with its major end-product angiotensin II (Ang II) plays a fundamental role in blood pressure regulation through direct and indirect mechanisms. Pharmacologically, we can inhibit the RAS using angiotensin-converting enzyme inhibitors and AT1 receptor blocker. Inhibiting… Expand
First-line treatment of hypertension: critical appraisal of potential role of aliskiren and hydrochlorothiazide in a fixed combination
TLDR
Aliskiren has been investigated and shown to be superior to monotherapy with respect to blood pressure control and improvement in patient compliance with therapy and its combination with hydrochlorothiazide is effective in preventing cardiovascular events and mortality when end organ damage is present. Expand
Effects of Aliskiren on Stroke in Rats Expressing Human Renin and Angiotensinogen Genes
TLDR
Head-to-head comparison suggests that treatment with aliskiren before and during cerebral ischemia is at least as effective as candesartan in double transgenic rats, and improves neurological outcome 7 days post-ischemia. Expand
The Renin-Angiotensin System Modulates Inflammatory Processes in Atherosclerosis: Evidence from Basic Research and Clinical Studies
TLDR
Basic research and animal studies strongly support angiotensin II as a proinflammatory mediator, which directly induces atherosclerotic plaque development and heart remodeling and improves prognosis of patients with cardiovascular disease even in settings of normal baseline blood pressure. Expand
Therapeutic inhibition of the renin angiotensin aldosterone system
  • D. Laight
  • Medicine
  • Expert opinion on therapeutic patents
  • 2009
TLDR
Each intervention of therapeutic anti-RAAS intervention has merits and demerits with implications for RAAS ‘escape’ phenomena, ‘dual inhibition’ therapy, long-term clinical efficacy and adverse drug reactions. Expand
Role of the renin-angiotensin system in autoimmune inflammation of the central nervous system
TLDR
A pivotal role of the RAS is suggested in autoimmune inflammation of the central nervous system and RAS blockade is identified as a potential new target for multiple sclerosis therapy. Expand
Aliskiren and valsartan in combination is a promising therapy for hypertensive renal injury in rats
TLDR
The results suggest that therapies aimed at different targets within the RAAS may have additional effects in attenuating structural injury in experimental hypertensive nephropathy. Expand
Chapter 5 Case History on Tekturna®/Rasilez® (Aliskiren), a Highly Efficacious Direct Oral Renin Inhibitor as a New Therapy for Hypertension
TLDR
Aliskiren has demonstrated orally active anti-hypertensive efficacy and end-organ protection and is safe and well-tolerated in pre-clinical and clinical trials. Expand
Direct Renin Inhibition in a Rat Model of Chronic Allograft Injury
TLDR
The renin inhibitor aliskiren does not slow the progression of chronic allograft dysfunction, and it is suggested that the lack of protection might be due to reduced formation of the protective Ang II breakdown products such as Ang (1–7) or due to unchanged intrarenal RAS activity demonstrated by urinary angiotensinogen levels. Expand
Normalizing Plasma Renin Activity in Experimental Dilated Cardiomyopathy: Effects on Edema, Cachexia, and Survival
TLDR
The normalization of plasma renin activity retards the progression of experimental HF by improving cardiac systolic function, reducing the development of systemic edema, cachexia/sarcopenia, and mortality. Expand
Left ventricular hypertrophy and renin-angiotensin system blockade
TLDR
Large clinical trials evaluating the blockade of the RAS with angiotensin-converting enzyme inhibitors or angiotENSin receptor blockers have demonstrated an ability to prevent progression and induce regression of left ventricular mass, thereby reducing the significant and independent cardiovascular risk conferred by LVH. Expand
...
1
2
3
4
...

References

SHOWING 1-10 OF 21 REFERENCES
Direct renin inhibition with aliskiren in hypertension and target organ damage.
  • D. Müller, F. Luft
  • Medicine
  • Clinical journal of the American Society of Nephrology : CJASN
  • 2006
TLDR
Aliskiren, a once-daily, orally effective, small-molecule renin inhibitor, is now available to address angiotensin production directly at its rate-limiting step, and offers a novel circumvention. Expand
Renin inhibition
  • M. Azizi
  • Medicine
  • Current opinion in nephrology and hypertension
  • 2006
TLDR
It remains unclear, however, as to how to optimize the renin-angiotensin system blockade to maximize cardiovascular and renal benefits, in this context, renin inhibition to render the ren in-angiotsin system fully quiescent is a new possibility requiring further study. Expand
Aliskiren, a novel renin inhibitor, is renoprotective in a model of advanced diabetic nephropathy in rats
TLDR
These findings suggest that therapies aimed at different targets within the RAS may not have identical effects in attenuating structural injury in experimental diabetic nephropathy. Expand
Angiotensin II Suppression in Humans by the Orally Active Renin Inhibitor Aliskiren (SPP100): Comparison With Enalapril
TLDR
Aliskiren has the potential to become the first orally active renin inhibitor that provides a true alternative to ACE-inhibitors and Ang II receptor antagonists in therapy for hypertension and other cardiovascular and renal diseases. Expand
Aldosterone Synthase Inhibitor Ameliorates Angiotensin II–Induced Organ Damage
TLDR
Aldosterone plays a key role in the pathogenesis of Ang II–induced organ damage and the present results show that aldosterone produced in the adrenals is the main source of cardiac ald testosterone. Expand
Plasma renin activity levels in hypertensive persons: their wide range and lack of suppression in diabetic and in most elderly patients.
TLDR
A large community sample of hypertensive patients reveals a wide distribution of activity level, with identifiable differences according to ethnicity, age, and sex but not diabetic status; however, these demographic differences were more quantitative than qualitative and do not provide a useful basis for estimation of the activity of the RAS. Expand
Mineralocorticoid Receptor Affects AP-1 and Nuclear Factor-&kgr;B Activation in Angiotensin II–Induced Cardiac Injury
TLDR
Findings show that aldosterone promotes hypertrophy, cardiac remodeling, and fibrosis, independent of blood pressure, in rats double transgenic for the human renin and angiotensinogen genes. Expand
Low-dose renin inhibitor and low-dose AT1-receptor blocker therapy ameliorate target-organ damage in rats harbouring human renin and angiotensinogen genes
TLDR
It is suggested that renin-angiotensin system (RAS) inhibition ameliorates target-organ damage in an Ang II-driven model of hypertension and answers the question of BP-lowering versus RAS inhibition. Expand
Aliskiren, a Human Renin Inhibitor, Ameliorates Cardiac and Renal Damage in Double-Transgenic Rats
TLDR
It is concluded that in dTGR, equieffective antihypertensive doses of Val or aliskiren attenuated end-organ damage and compares favorably to angiotensin receptor blockade in reversing organ damage. Expand
Species specificity of renin kinetics in transgenic rats harboring the human renin and angiotensinogen genes.
  • D. Ganten, J. Wagner, +7 authors U. Ganten
  • Biology, Medicine
  • Proceedings of the National Academy of Sciences of the United States of America
  • 1992
TLDR
Transgenic rat models with human-specific enzyme kinetics permit primate-specific analyses in non-primate in vivo and in vitro experimental systems and reports here the development of transgenic rats carrying the human angiotensinogen TGR-(hAOGEN) and human renin TGR(hREN) genes. Expand
...
1
2
3
...